



Colleagues & Clinicians,

When the PAX test initially launched in January 2023, Nextmune's R & D team had determined a positivity threshold of 30ng/mL. This was decided after employing several different methods for threshold determination. Setting a threshold is not an exact science and because the PAX is a living test, our team expected that the 30ng/mL threshold would possibly need to be revised after collection of further clinical data.

We have now collected several thousand patient sera over the last 2 months. The veterinary community has also supplied us with excellent clinical histories, including both general practitioners and dermatology specialists. Through our review of these data, it has become clear there are allergens that are not meeting the threshold of 30ng/mL and yet the patients have clinical indications of allergy to such allergens.

Based on this extensive data collection and clinical evidence, we have determined that our current threshold should be lowered to 28ng/mL. Nextmune will continue to refine the PAX testing process and will soon begin the extensive scanning of most allergen components known to date to identify additional relevant allergens to add to future versions of this test.

We continue to be dedicated to industry leading transparency on our test, including scientific methodology, quality control processes, and threshold determinations. Our veterinary dermatology team is also available to answer any clinical questions.

For additional questions regarding this change, please contact us at PAX@nextmune.com.

Dr. Thierry Olivry
Head of Research & Development
Nextmune